A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,900 shares of ITOS stock, worth $224,660. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,900
Previous 13,100 82.44%
Holding current value
$224,660
Previous $178,000 98.88%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.33 - $18.09 $4.87 Million - $8.53 Million
-471,332 Reduced 40.33%
697,332 $10.3 Million
Q1 2024

May 15, 2024

BUY
$9.89 - $13.64 $384,483 - $530,268
38,876 Added 3.44%
1,168,664 $15.9 Million
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $1.05 Million - $1.35 Million
122,216 Added 12.13%
1,129,788 $12.4 Million
Q3 2023

Nov 14, 2023

SELL
$10.95 - $14.6 $2.06 Million - $2.74 Million
-187,697 Reduced 15.7%
1,007,572 $11 Million
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $3.21 Million - $4.48 Million
-248,231 Reduced 17.2%
1,195,269 $15.8 Million
Q1 2023

May 15, 2023

BUY
$13.02 - $22.62 $1.15 Million - $1.99 Million
88,073 Added 6.5%
1,443,500 $19.6 Million
Q4 2022

Feb 14, 2023

BUY
$17.77 - $21.6 $596,076 - $724,550
33,544 Added 2.54%
1,355,427 $26.5 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $11.3 Million - $16.6 Million
608,171 Added 85.21%
1,321,883 $25.2 Million
Q2 2022

Aug 15, 2022

BUY
$16.57 - $35.1 $3.19 Million - $6.75 Million
192,241 Added 36.87%
713,712 $14.7 Million
Q1 2022

May 16, 2022

SELL
$31.92 - $47.45 $15.2 Million - $22.7 Million
-477,470 Reduced 47.8%
521,471 $16.8 Million
Q4 2021

Feb 14, 2022

BUY
$26.23 - $47.86 $617,008 - $1.13 Million
23,523 Added 2.41%
998,941 $0
Q3 2021

Nov 15, 2021

SELL
$23.91 - $29.58 $453,763 - $561,369
-18,978 Reduced 1.91%
975,418 $26.3 Million
Q2 2021

Aug 16, 2021

BUY
$17.9 - $36.1 $8.65 Million - $17.5 Million
483,398 Added 94.6%
994,396 $0
Q1 2021

May 17, 2021

SELL
$30.86 - $44.2 $8.84 Million - $12.7 Million
-286,316 Reduced 35.91%
510,998 $17.5 Million
Q4 2020

Feb 16, 2021

SELL
$21.59 - $33.95 $2.18 Million - $3.43 Million
-100,975 Reduced 11.24%
797,314 $27 Million
Q3 2020

Nov 16, 2020

BUY
$17.57 - $32.92 $15.8 Million - $29.6 Million
898,289 New
898,289 $22.2 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $334M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.